STOCK TITAN

Vanda Pharmaceuticals (VNDA) SEC Filings

VNDA NASDAQ

Vanda Pharmaceuticals Inc. filings document the company's operating results, commercial product disclosures, regulatory developments, and public-company governance. Form 8-K reports include quarterly and annual financial results, product-related events for NEREUS and BYSANTI, clinical and regulatory forward-looking language, and management communications about commercial strategy.

The company's proxy and governance filings cover director elections, board composition, executive compensation, equity awards, annual bonus and salary decisions, and related stockholder voting matters. Other current reports document board expansion, officer changes, compensatory arrangements, exhibits to press releases, and risk-oriented disclosures tied to Vanda's marketed products and development pipeline.

Rhea-AI Summary

Vanda Pharmaceuticals Inc. (VNDA) entered into a settlement and license agreement with MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited concerning MSN’s proposed U.S. generic tasimelteon oral suspension. The agreement grants MSN a non-exclusive, royalty-free U.S. license beginning in the first quarter of 2040, with earlier market entry possible under specified circumstances.

MSN receives limited rights to manufacture and import the product starting 180 days before the license date, and to hold customer discussions 30 days and pricing and contracting discussions 14 days before it. Vanda and MSN will submit the agreement for FTC and DOJ review, file a stipulated order to dismiss the litigation, and submit a consent judgment and permanent injunction to the court for approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.13%
Tags
current report
-
Rhea-AI Summary

Vanda Pharmaceuticals Inc. (VNDA) common stock is the subject of an amended beneficial-ownership report from AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC. Each reports beneficial ownership of 2,096,939 shares, or 3.47% of the class, for the September 30, 2026 event date. Both entities report shared voting power over 1,971,025 shares and shared dispositive power over 2,096,939 shares, with no sole voting or dispositive power. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
ownership
-
Rhea-AI Summary

Vanda Pharmaceuticals Inc. is the issuer of the common stock for which State Street Corporation reported beneficial ownership of 3,010,531 shares, equal to 5% of the class, for the September 30, 2026 event date. State Street reported shared voting power over 2,938,155 shares and shared dispositive power over 3,010,531 shares; its sole voting and dispositive powers were each 0 shares. The listed subsidiaries are SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, and State Street Global Advisors Trust Company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
ownership
Rhea-AI Summary

Vanda Pharmaceuticals Inc. director Charles Cliff Duncan reported direct purchases totaling 10,000 shares: 750 shares at a weighted-average price of $3.7959 per share on November 3, 2026; 3,447 shares at a weighted-average price of $3.8210 per share on November 4, 2026; and 5,803 shares at a weighted-average price of $3.8042 per share on November 5, 2026. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
insider
-
Rhea-AI Summary

Vanda Pharmaceuticals Inc. (VNDA) reported third-quarter revenue of $69.8 million, compared with $56.3 million a year earlier, and a net loss of $22.6 million. Third-quarter sales included $38.8 million from Fanapt, $21.7 million from HETLIOZ, $7.7 million from PONVORY and $1.6 million from NEREUS.

For the first nine months, revenue was $172.1 million, versus $158.9 million, while net loss widened to $133.6 million from $79.3 million. Net cash used in operating activities was $109.7 million, compared with $80.0 million. Fanapt nine-month sales rose to $104.3 million from $84.1 million; HETLIOZ sales declined to $43.2 million from $55.0 million. Vanda cited generic competition and elevated specialty-pharmacy inventory as factors affecting HETLIOZ sales.

At September 30, 2026, Vanda had $61.9 million in cash and cash equivalents and $78.6 million in marketable securities, compared with $84.9 million and $179.0 million, respectively, at December 31, 2025. Based on its operating plans, Vanda said it believes those resources plus cash from product sales will be sufficient for at least the next 12 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
quarterly report
-
Rhea-AI Summary

Vanda Pharmaceuticals Inc. reported third-quarter 2026 revenue of $69.8 million, up 24% from $56.3 million in Q3 2025 and 38% from $50.5 million in Q2 2026. Operating expenses were $93.3 million, up 7% year over year but down 18% from Q2. Net loss was $22.6 million, compared with $22.6 million in Q3 2025 and $62.5 million in Q2; nine-month net loss was $133.6 million versus $79.3 million in 2025.

Product sales included Fanapt at $38.8 million, HETLIOZ at $21.7 million, PONVORY at $7.7 million and NEREUS at $1.6 million. Cash, cash equivalents and marketable securities totaled $140.5 million as of September 30, 2026, down $29.5 million during Q3. Vanda expects full-year 2026 revenue of greater than $240 million.

Vanda reported positive Phase III results for NEREUS in preventing GLP-1-associated vomiting and plans to discuss the data with the FDA and submit an sNDA. HETLIOZ had positive topline Phase III results for Delayed Sleep-Wake Phase Disorder; Vanda plans FDA discussions and an sNDA. Quimilza’s BLA for GPP is under FDA review, with a December 12, 2026 PDUFA target action date. BYSANTI’s launch is expected in Q4 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
current report
Rhea-AI Summary

Vanda Pharmaceuticals Inc. (VNDA) is the issuer named in a Schedule 13G where BlackRock Portfolio Management LLC reported beneficial ownership of 3,587,013 common shares, or 5.9% of the class, as of September 30, 2026. BlackRock Portfolio Management LLC reported sole voting power over 3,228,683 shares and sole dispositive power over 3,587,013 shares, with no shared voting or dispositive power. The disclosure states that various persons may direct dividends or sale proceeds, but no single person's interest exceeds 5% of Vanda's outstanding common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
ownership
-
Rhea-AI Summary

For Vanda Pharmaceuticals Inc. (VNDA), Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 4,260,038 shares, equal to 7.0% of the class.

The securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC and Israel A. Englander. The three reporting persons state that this disclosure alone should not be construed as an admission that they beneficially own securities held by those entities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
ownership
-
Rhea-AI Summary

Vanda Pharmaceuticals Inc. (VNDA) is reported to have a significant shareholder group consisting of Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. These reporting persons collectively report beneficial ownership of 3,376,401 shares of Vanda common stock, representing 5.6% of the outstanding class.

They report shared voting and shared dispositive power over all 3,376,401 shares, and no sole voting or dispositive power. The shares are held by entities over which Millennium Management LLC and related managers have voting control and investment discretion, and the reporting persons state that this should not, by itself, be construed as an admission of beneficial ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
ownership
Rhea-AI Summary

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report a passive ownership stake in Vanda Pharmaceuticals Inc. common stock. They disclose beneficial ownership of 3,497,695 shares, representing 5.82% of Vanda’s outstanding common stock as of the filing date.

Both entities report no sole voting or dispositive power. They have shared voting power over 3,313,298 shares and shared dispositive power over all 3,497,695 shares. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and the Schedule is filed on behalf of both.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
ownership

FAQ

How many Vanda Pharmaceuticals (VNDA) SEC filings are available on StockTitan?

StockTitan tracks 69 SEC filings for Vanda Pharmaceuticals (VNDA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Vanda Pharmaceuticals (VNDA)?

The most recent SEC filing for Vanda Pharmaceuticals (VNDA) was filed on November 20, 2026.